ICP
CRSP icon

Interchange Capital Partners’s CRISPR Therapeutics CRSP Stock Holding History

Interchange Capital Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$245K Sell
4,498
-2,269
-34% -$120K 0.05% 354
2026
Q1 		$230K Sell
6,767
-387
-5% -$20.4K 0.07% 242
2025
Q4 		$375K Buy
7,154
+151
+2% +$9.04K 0.07% 249
2025
Q3 		$454K Buy
7,003
+283
+4% +$16.2K 0.09% 198
2025
Q2 		$327K Sell
6,720
-699
-9% -$27.1K 0.08% 205
2025
Q1 		$252K Sell
7,419
-1,121
-13% -$47.5K 0.07% 225
2024
Q4 		$313K Buy
8,540
+331
+4% +$15.6K 0.11% 179
2024
Q3 		$386K Sell
8,209
-532
-6% -$27K 0.14% 169
2024
Q2 		$472K Buy
8,741
+1,616
+23% +$93.5K 0.17% 144
2024
Q1 		$489K Buy
7,125
+505
+8% +$36.2K 0.33% 72
2023
Q4 		$413K Buy
6,620
+855
+15% +$47.3K 0.31% 76
2023
Q3 		$262K Buy
5,765
+330
+6% +$17K 0.21% 120
2023
Q2 		$323K Buy
5,435
+607
+13% +$34.4K 0.25% 99
2023
Q1 		$218K Buy
+4,828
New +$234K 0.12% 187
2022
Q4 		– Sell
-5,714
Closed -$373K – 132
2022
Q3 		$373K Sell
5,714
-1,748
-23% -$127K 0.41% 67
2022
Q2 		$453K Buy
7,462
+121
+2% +$7.11K 0.51% 57
2022
Q1 		$460K Buy
7,341
+1,059
+17% +$66.5K 0.47% 67
2021
Q4 		$476K Buy
+6,282
New +$549K 0.48% 70
2021
Q2 		– Sell
-7,568
Closed -$1.01M – 123
2021
Q1 		$1.01M Sell
7,568
-2,185
-22% -$330K 0.55% 53
2020
Q4 		$1.49M Buy
+9,753
New +$1.15M 0.81% 22

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Interchange Capital Partners's CRSP Position: Q2 2026 in Review

Interchange Capital Partners reduced its CRISPR Therapeutics (CRSP) stake by 34% in Q2 2026, selling an estimated $120K and leaving 4,498 shares worth $245K. The position accounts for 0.05% of the portfolio, ranked #354.

Interchange Capital Partners first reported a position in CRSP in Q4 2020 and has held it in 20 quarters since. The position peaked at $1.49M in Q4 2020. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Interchange Capital Partners held 4,498 shares of CRISPR Therapeutics worth $245K as of Q2 2026.
  • Interchange Capital Partners sold 2,269 CRISPR Therapeutics shares in Q2 2026, an estimated $120K.
  • CRISPR Therapeutics made up 0.05% of Interchange Capital Partners's portfolio in Q2 2026, its #354 holding.
  • Interchange Capital Partners first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 20 quarters since.
  • Interchange Capital Partners's CRISPR Therapeutics position peaked at $1.49M in Q4 2020.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Interchange Capital Partners's 13F filing for Q2 2026, filed 20 Jul 2026.